A low endotoxin response is reassuring only if the assay can detect endotoxin in that sample. Material components can suppress or increase the measured response. Suitability testing investigates those effects, while storage studies can address a different problem: whether endotoxin remains detectable as the sample changes over time.
Ask what happens to a known addition in the sample
An inhibition or enhancement assessment compares the response to a known endotoxin addition in the sample with the expected response. The unspiked sample contribution must be accounted for when calculating recovery.
For an original quantitative example, suppose a sample reads 0.10 EU/mL and the same preparation with an added 0.50 EU/mL reads 0.40 EU/mL. The incremental recovery is (0.40 − 0.10)/0.50 × 100 = 60%. Whether that meets the method’s criterion is a separate decision.
| Control | Main question |
|---|---|
| Reagent blank | Is there background contribution without sample? |
| Standards | Does the reference response support calibration? |
| Unspiked sample | What response does the sample produce? |
| Spiked sample | How does the matrix affect a known addition? |
Do not treat an apparently low unspiked result as valid if the associated control shows that the assay cannot recover the addition appropriately. The control qualifies interpretation of the result.
Balance relief of interference with final sensitivity
FDA’s March 2026 guidance explains that dilution can reduce interference, but links the maximum valid dilution to detecting the applicable endotoxin limit. Dilution is therefore constrained by the sensitivity required on the original-sample basis.FDA — Pyrogen and endotoxins testing, Edition 2 (opens in a new tab)
An original example makes the trade-off visible: an assay bound of 0.01 EU/mL becomes 1 EU/mL on the original basis after a 100-fold dilution. A quieter matrix does not automatically make that final bound adequate for the question being asked.
The dilution must remain connected with the defined method and specification. It should not be increased simply until an unwelcome result disappears.
Kang and colleagues observed matrix-dependent interference when comparing recombinant and LAL assays in biopharmaceuticals. Their use of dilution was supported within the examined systems, rather than a guarantee for all future samples.Kang and colleagues — Matrix interference in recombinant and LAL assays (opens in a new tab)
Distinguish a fresh spike from a held sample
FDA also notes that sample storage and handling can affect endotoxin detection and that purified and native endotoxin sources can behave differently. The relevant holding conditions therefore need evidence rather than an assumed universal stability period.FDA — Pyrogen and endotoxins testing, Edition 2 (opens in a new tab)
A fresh spike added shortly before measurement asks whether that addition is detectable now. Endotoxin already present during storage may have experienced different interactions. Passing the fresh control does not automatically reconstruct that earlier history.
Schwarz and colleagues investigated masked endotoxin in defined formulations. They found that some material with diminished factor-C-based detection retained responses in cell-based systems. The study shows why loss of assay detectability should not be equated with destruction of the target or disappearance of biological activity.Schwarz and colleagues — Biological activity of masked endotoxin (opens in a new tab)
That phenomenon is not a diagnosis for every unexpectedly low result. A specific sample needs its own evidence before masking is assigned as the cause.
Describe what remains unresolved when suitability fails
An invalid or interfered test is not the same as a high measured endotoxin result, and it is not a demonstrated absence. It indicates that the procedure has not supplied an interpretable answer under those conditions.
A useful report distinguishes the sample response, control outcome, preparation and final limit. If a repeat procedure is justified, retain the original result and the reason for the change rather than presenting the later number without context.
The conclusion should identify the scope of the evidence: immediate assay suitability, a defined hold-time assessment, or both. This is more informative than a generic statement that the product “passed endotoxin testing”.
Sources and further detail
- FDA — Pyrogen and endotoxins testing, Edition 2 (opens in a new tab)
March 2026, questions 3 and 12: sample handling and constrained dilution. No clinical acceptance limit or operating recipe reproduced.
- Kang and colleagues — Matrix interference in recombinant and LAL assays (opens in a new tab)
Primary 2024 study; dilution findings are restricted to the examined materials.
- Schwarz and colleagues — Biological activity of masked endotoxin (opens in a new tab)
Scientific Reports 7, 44750 (2017), DOI 10.1038/srep44750. Primary masked-endotoxin experiments; findings are not assumed for any supplied product.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.